Aprea Therapeutics, Inc. (APRE)
Largest Insider Buys in Sector
APRE Stock Price History Chart
APRE Stock Performance
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Insider Activity of Aprea Therapeutics, Inc.
Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $287,903 and sold $29,583 worth of Aprea Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $162,430 and sold $20.95M worth of stock each year.
Highest buying activity among insiders over the last 12 months: HENNEMAN JOHN B III (director) — $250,047. Seizinger Bernd R. (director) — $153,619. Duey Marc (director) — $132,190.
The last purchase of 500 shares for transaction amount of $1,958 was made by Gilad Oren (President/CEO) on 2024‑10‑23.
List of Insider Buy and Sell Transactions, Aprea Therapeutics, Inc.
| 2024-10-23 | President/CEO | 500 0.0086% | $3.92 | $1,958 | 0.00% | |||
| 2024-10-18 | Sale | director | 6,462 0.1238% | $4.58 | $29,583 | -9.32% | ||
| 2024-10-16 | director | 30,000 0.8303% | $4.39 | $131,700 | +18.00% | |||
| 2024-10-15 | President/CEO | 250 0.0046% | $2.90 | $725 | +31.48% | |||
| 2024-10-14 | President/CEO | 1,000 0.0163% | $2.59 | $2,590 | +55.86% | |||
| 2024-10-14 | director | 190 0.0031% | $2.58 | $490 | +55.86% | |||
| 2024-10-11 | director | 10,000 0.169% | $2.68 | $26,800 | +52.69% | |||
| 2024-10-11 | SrVP/CFO/Prin Fin & Acct Ofcr | 50 0.0008% | $2.46 | $123 | +52.69% | |||
| 2024-10-10 | President/CEO | 150 0.0024% | $2.54 | $381 | +55.31% | |||
| 2024-10-10 | SrVP/CFO/Prin Fin & Acct Ofcr | 450 0.0074% | $2.61 | $1,175 | +55.31% | |||
| 2024-03-13 | President, CEO | 2,000 0.0683% | $7.29 | $14,580 | -22.97% | |||
| 2024-03-13 | director | 6,860 0.2342% | $7.29 | $50,009 | -22.97% | |||
| 2024-03-13 | SrVP/CFO/Prin Fin & Acct Ofcr | 1,010 0.0345% | $7.29 | $7,363 | -22.97% | |||
| 2024-03-13 | director | 6,860 0.2342% | $7.29 | $50,009 | -22.97% | |||
| 2023-06-07 | director | 6,029 0.1917% | $3.68 | $22,192 | +21.41% | |||
| 2023-06-06 | director | 4,068 0.1208% | $3.63 | $14,764 | +13.87% | |||
| 2020-12-28 | Sale | 10 percent owner | 500,000 2.4014% | $5.58 | $2.79M | -11.73% | ||
| 2020-10-05 | Sale | Former 10% holder | 175,000 0.7844% | $25.30 | $4.43M | -80.91% | ||
| 2020-07-07 | Sale | 10 percent owner | 241,703 1.1593% | $34.55 | $8.35M | -79.65% | ||
| 2020-06-16 | Sale | Former 10% holder | 120,164 0.5556% | $33.30 | $4M | -38.45% |
Insider Historical Profitability
| Gilad Oren | President/CEO | 333395 6.1377% | $4.08 | 5 | 0 | |
| Duey Marc | director | 233651 4.3015% | $4.08 | 2 | 1 | |
| Seizinger Bernd R. | director | 44730 0.8235% | $4.08 | 4 | 0 | +17.64% |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 19368 0.3566% | $4.08 | 3 | 0 | |
| HENNEMAN JOHN B III | director | 8139 0.1498% | $4.08 | 2 | 0 | +53.58% |